Bibliografie tematiche / Low molecular weight heparin / Libri
Segui questo link per vedere altri tipi di pubblicazioni sul tema: Low molecular weight heparin.

Libri sul tema "Low molecular weight heparin"

Autore: Grafiati
Pubblicato: 4 giugno 2021
Ultima modifica: 10 marzo 2023

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 libri per l'attività di ricerca sul tema "Low molecular weight heparin".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi i libri di molte aree scientifiche e compila una bibliografia corretta.

1

Barrowcliffe, Trevor W. Low molecular weight heparin. Chichester, West Sussex, England: Wiley, 1992.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Hyers, Thomas M. Treatment handbook of low-molecular-weight heparin. London: Science Press, 2000.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Thromoprophylaxis with low-molecular-weight heparins. London: Current Medicine Group, 2006.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Christian, Doutremepuich, a cura di. Low molecular weight heparins in clinical practice. New York: Dekker, 1992.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

1940-, Kher André, Sarret Monique 1938- e Toulemonde Francis 1926-, a cura di. Low molecular weight heparin therapy: An evaluation of clinical trials evidence. New York: Marcel Dekker, 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Holmer, Erik. Heparin and its low molecular weight derivatives: Basic and applied studies in the development of a new antithrombotic drug. Uppsala: Sveriges Lantbruksuniversitet, 1987.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Maguire, Jacinta Marie. Low molecular weight heparin regime or unfractionated heparin and as pirin in the treatment of unstable angina. [S.l: The Author], 1994.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Shukla, Vijay K. Low molecular weight heparins for major orthopedic surgery: A case for clinical outcomes. Ottawa, Ont: Canadian Coordinating Office for Health Technology Assessment, 1998.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2010. http://dx.doi.org/10.1002/9783527629978.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Bäckvall, Helena, e Janne Lehtiö, a cura di. The Low Molecular Weight Proteome. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7209-4.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
11

Nightingale, Philip D. Low molecular weight halocarbons in seawater. Norwich: University of East Anglia, 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
12

Haug, G., e H. Hoffmann, a cura di. Pyrethroid Residues, Immunoassays for Low Molecular Weight Compounds. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74846-2.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
13

Blass, W. Pyrethroid residues, immunoassays for low molecular weight compounds. Berlin: Springer-Verlag, 1990.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
14

Bäckvall, Helena. The low molecular weight proteome: Methods and protocols. New York: Springer, 2013.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
15

Niemelä, Klaus. Low-molecular-weight organic compounds in birch kraft black liquor. Helsinki: Suomalainen Tiedeakatemia, 1990.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
16

Zhu, Yibo. Two-dimensional material-based nanosensors for detection of low-molecular-weight molecules. [New York, N.Y.?]: [publisher not identified], 2018.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
17

Astrid, Sigel, e Sigel Helmut, a cura di. Probing of proteins by metal ions and their low-molecular-weight complexes. New York: Marcel Dekker, 2001.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
18

McCallum, N. K. A specific method for the analysis of low molecular weight phenols using pentafluorobenzyl ethers. Lower Hutt: Chemistry Division, Dept. of Scientific and Industrial Research, 1986.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
19

Layton, Guy Timothy. The immunogenicity and allergenicity of low molecular weight chemicals: Chlorhexidine as the model hapten. Birmingham: University of Birmingham, 1985.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
20

Pierson, Janice Rose. A study of the expression of the low molecular weight cytokeratins in cervical pearls. [S.l: The Author], 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
21

L, Newton Gerald, e United States. National Aeronautics and Space Administration., a cura di. Determination of low molecular weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. [Washington, DC]: National Aeronautics and Space Administration, 1988.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
22

Morales, Roman Padilla. High density polyethylene modified with a low molecular weight ionomer and the precursor acid copolymer. Ottawa: National Library of Canada, 1994.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
23

Yang, Jaeyoung. Micro and Nanoscale Aptasensors for Detection of Low Molecular Weight Biomarkers Towards Clinical Diagnostic Applications. [New York, N.Y.?]: [publisher not identified], 2015.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
24

Latorre, Sandra Stefanie. Formation of low molecular weight organic compounds from UV disinfection of chlorinated water containing humic substances. Ottawa: National Library of Canada, 2003.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
25

Blackwell, Malcolm Peter. Investigation of a biochemical marker of pulmonary eosinophil influx as a predictive assay for low molecular weight respiratory sensitisers. [Derby: University of Derby], 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
26

Kägi, Jeremias H. R., 1930- e Kojima Yutaka 1933-, a cura di. Metallothionein II: Proceedings of the Second International Meeting on Metallothionein and Other Low Molecular Weight Metal-binding Proteins : Zürich, August 21-24, 1985. Basel: Birkhäuser Verlag, 1987.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
27

Laturnus, Frank. Bildung und Abgabe kurzkettiger halogenierter Kohlenwasserstoffe durch Makroalgen der Polarregionen =: Formation and release of low-molecular weight halogenated hydrocarbons by macroalgae from polar regions. Bremerhaven: Alfred-Wegener-Institut für Polar- und Meeresforschung, 1993.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
28

Low Molecular Weight Haparins. 3a ed. BC Decker Inc., 1998.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
29

Samama, Meyer M. Low Molecular Weight Heparin and Its Clinical Use: Journal: Haemostasis, Vol. 16, 1985 (Low Molecular Weight Heparin & Its Clinical Use). S. Karger AG (Switzerland), 1986.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
30

Low Molecular Weight Heparins. Decker Periodicals, Canada, 1994.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
31

Breddin, H. K. Low Molecular Weight Heparins. S Karger AG, 1988.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
32

Power, Trevor David. Derivatization of low molecular weight heparin with polyethylene glycol monomethyl ether (MPEG). 1995.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
33

Sarret/Kher/tou. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Informa Healthcare, 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
34

Sarret, Monique, Andre Kher e Francis Toulemonde. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Taylor & Francis Group, 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
35

Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: M. Dekker, 1994.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
36

Kakkar, V. V. Low-Molecular-Weight Heparins - New Fronteirs in Antithrombotic Therapy (Haemostasis). S Karger Pub, 1997.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
37

Low-Molecular-Weight Heparins: A New Therapeutic Approach to Thrombosis Proceedings (Journal - Haemostasis , Vol 26, Suppl. 2). S. Karger AG (Switzerland), 1996.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
38

MacCallum, Niall S. Management of oncological complications in the ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0376.

Testo completo
Abstract (sommario):
Important treatment complications relevant to critical care are discussed. Cancer-related pain is complex and requires multidisciplinary care, particularly in the peri-operative setting. Chemotherapeutic complications include pancytopenia, cardiac, pulmonary, renal, gastrointestinal, hepatic, and neurotoxicity. Radiotherapy complications include cardiac, pulmonary, and gastrointestinal toxicity. In general, management includes assessing the risk-benefit to cytotoxic therapy withdrawal and supportive care. There is a paucity of proven treatment options for most complications, althoughcertain therapies are used to prevent and/or treat complications (e.g. tumour lysis syndrome). Thromboembolic disease is a common cause of mortality and morbidity; low molecular weight heparin therapy may be superior to oral anticoagulation.
Gli stili APA, Harvard, Vancouver, ISO e altri
39

Peppelenbosch, A. G., e Martijn Poeze. Ischaemic bowel in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0186.

Testo completo
Abstract (sommario):
Intestinal ischaemia is caused by occlusion of the visceral arteries, thrombosis of the mesenteric veins, or by (low-flow) non-occlusive mesenteric ischaemia (NOMI). Each condition has a specific diagnostic and therapeutic work-up and prognostic significance. The incidence of acute mesenteric infarction is as low as 0.63 cases/100,000 person years, but overall mortality rates remains high at 74%. In general, a high index of suspicion is necessary and should be followed by administering therapeutic low molecular weight heparin or systemic heparin infusion. In these patients resuscitation and organ support are essential, but should not delay diagnostic work-up, including CT-angiography. With arterial occlusion, revascularization should be performed if indicated, preferentially using endovascular techniques prior to laparotomy. For venous occlusion, thrombolytic therapy directly into the superior mesenteric artery or venous thrombectomy can be performed, followed by laparotomy. The treatment of NOMI is to treat the underlying cause.
Gli stili APA, Harvard, Vancouver, ISO e altri
40

Kilkelly, Shannon. Coagulation System. A cura di Matthew D. McEvoy e Cory M. Furse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190226459.003.0090.

Testo completo
Abstract (sommario):
Despite the development of entirely new classes of anticoagulant medication, vitamin K antagonists like warfarin continue to be commonly prescribed for a wide range of cardiovascular diagnoses. Conversely, the advent of low molecular weight heparin has greatly simplified the use of the drug to the point that patients can dose themselves at home with no need for any type of monitoring. Given the widespread use of these medications, it is not surprising that an increasing number of patients requiring urgent or emergent surgery will present with a medically induced coagulopathy. Managing this coagulopathy requires assessment of the urgency of the operation, the patient’s volume status, and the need for reanticoagulation following surgical intervention.
Gli stili APA, Harvard, Vancouver, ISO e altri
41

Low Molecular Weight Organic Semiconductors. Vch Verlagsgesellschaft Mbh, 2009.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
42

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2010.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
43

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
44

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
45

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Limited, John, 2010.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
46

Chong, Ji Y., e Michael P. Lerario. Cancer and Coagulopathy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190495541.003.0019.

Testo completo
Abstract (sommario):
Advanced cancer is well known to cause a procoagulant state. The formation of sterile platelet thrombin vegetations on cardiac valves (i.e., nonbacterial thromboembolic disease) and arterial thrombosis are common etiologies of stroke in these patients. Despite preventative therapy with antiplatelet agents or low-molecular-weight heparins, stroke in cancer often portends a poor prognosis.
Gli stili APA, Harvard, Vancouver, ISO e altri
47

Ballal, Salma, e Ian A. Greer. Thromboembolic disorders in pregnancy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198713333.003.0037.

Testo completo
Abstract (sommario):
Thromboembolism in pregnancy remains a major cause of direct maternal mortality in the Western world. Thromboembolic events in pregnancy are spread across the three trimesters but the puerperium is the time of greatest risk with a relative risk of around 20-fold compared to the non-pregnant patient. When compared to the non-pregnant population where distal deep vein thrombosis is most common, most events in pregnancy are iliofemoral and left sided. Given the multi-hit nature of the problem, awareness of risk factors is important. The two most significant single risk factors in pregnancy for thromboembolism are history of previous venous thromboembolism and thrombophilia. The identification of risk factors will guide the use of thromboprophylaxis and assist diagnosis; however, objective diagnosis is required. Prophylaxis and treatment focuses on low-molecular-weight heparin, which is considered safe in pregnancy.
Gli stili APA, Harvard, Vancouver, ISO e altri
48

Bäckvall, Helena, e Janne Lehtiö. Low Molecular Weight Proteome: Methods and Protocols. Springer New York, 2016.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
49

Zemskov, V. M. Immunomodulating Effects of a Low Molecular Weight RNA. Routledge, 1992.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
50

Hayden, John. Low molecular weight organic acids in forest soils. 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
Ti possono interessare anche gli elenchi di altri tipi di fonti sul tema "Low molecular weight heparin":
Articoli di riviste Tesi
Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!

Vai alla bibliografia